Goldman Sachs initiated coverage of Soleno Therapeutics (SLNO) with a Buy rating and $125 price target The firm sees the company’s Vykat XR becoming a “foundational treatment” for Prader-Willi syndrome. The drug should grow into a blockbuster franchise while the recent pullback offers an attractive entry point into Soleno shares, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Buy Rating for Soleno Therapeutics: Strong Market Potential and Growth Opportunities with Vykat XR
- Positive Outlook for Soleno Therapeutics Amid Competitive Setback and Strong VYKAT XR Performance
- Video: Soleno Therapeutics stock rallies on competitor’s failed trial
- Micron reports Q4 beat, Instagram reports 3B MAUs: Morning Buzz
- Soleno Therapeutics rises 12.0%